Michael Stumvoll

Michael Stumvoll

Auto-generated profile, based on publicly available information

Michael Stumvoll

Department of Medicine, University of Leipzig, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe ENGAGE Consortium
The ENGAGE Consortium
TTThorgeir E Thorgeirsson
Thorgeir E Thorgeirsson
DGDaniel F Gudbjartsson
Daniel F Gudbjartsson
ISIda Surakka
Ida Surakka
JVJacqueline M Vink
Jacqueline M Vink
KSKari Stefansson
Kari Stefansson

1 November 2006 in Diabetes
Verified
Journal Article
Closed access
PDF file
MBMatthias BlühEr
Matthias BlühEr
SEStefan Engeli
Stefan Engeli
NKNora KlötIng
Nora KlötIng
JBJanin Berndt
Janin Berndt
MFMathias Fasshauer
Mathias Fasshauer
MSMichael Stumvoll
Michael Stumvoll
The endocannabinoid system has been suspected to contribute to the association of visceral fat accumulation with metabolic diseases. We determined whether circulating endocannabinoids are related to visceral adipose tissue mass in lean, subcutaneous obese, and visceral obese subjects (10 men and 10 women in each group). We further measured expression of the cannabinoid type 1 (CB1) receptor and fatty acid amide hydrolase (FAAH) genes in paired samples of subcutaneous and visceral adipose tissue in all 60 subjects. Circulating 2-arachidonoyl glycerol (2-AG) was significantly correlated with body fat (r = 0.45, P = 0.03), visceral fat mass (r = 0.44, P = 0.003), and fasting plasma insulin concentrations (r = 0.41, P = 0.001) but negatively correlated to glucose infusion rate during clamp (r = 0.39, P = 0.009). In visceral adipose tissue, CB1 mRNA expression was negatively correlated with visceral fat mass (r = 0.32, P = 0.01), fasting insulin (r = 0.48, P < 0.001), and circulating 2-AG (r = 0.5, P < 0.001), whereas FAAH gene expression was negatively correlated with visceral fat mass (r = 0.39, P = 0.01) and circulating 2-AG (r = 0.77, P < 0.001). Our findings suggest that abdominal fat accumulation is a critical correlate of the dysregulation of the peripheral endocannabinoid system in human obesity. Thus, the endocannabinoid system may represent a primary target for the treatment of abdominal obesity and associated metabolic changes.

8 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SFSofia Kirke Forslund
Sofia Kirke Forslund
RCRima Chakaroun
Rima Chakaroun
MZMaria Zimmermann-Kogadeeva
Maria Zimmermann-Kogadeeva
LMLajos Marko
Lajos Marko
JAJudith Aron-Wisnewsky
Judith Aron-Wisnewsky
PBPeer Bork
Peer Bork

1 June 2014 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
MFMathias Fasshauer
Mathias Fasshauer
MBMatthias Blüher
Matthias Blüher
MSMichael Stumvoll
Michael Stumvoll

1 January 2011 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
PDF file
AHAnnette Horstmann
Annette Horstmann
FBFranziska P. Busse
Franziska P. Busse
DMDavid Mathar
David Mathar
KMKarsten Müller
Karsten Müller
JLJöran Lepsien
Jöran Lepsien
BPBurkhard Pleger
Burkhard Pleger
Gender differences in the regulation of body-weight are well documented. Here, we assessed obesity-related influences of gender on brain structure as well as performance in the Iowa Gambling Task. This task requires evaluation of both immediate rewards and long-term outcomes and thus mirrors the trade-off between immediate reward from eating and the long-term effect of overeating on body-weight. In women, but not in men, we show that the preference for salient immediate rewards in the face of negative long-term consequences is higher in obese than in lean subjects. In addition, we report structural differences in the left dorsal striatum (i.e., putamen) and right dorsolateral prefrontal cortex for women only. Functionally, both regions are known to play complimentary roles in habitual and goal-directed control of behavior in motivational contexts. For women as well as men, gray matter volume correlates positively with measures of obesity in regions coding the value and saliency of food (i.e., nucleus accumbens, orbitofrontal cortex) as well as in the hypothalamus (i.e., the brain’s central homeostatic center). These differences between lean and obese subjects in hedonic and homeostatic control systems may reflect a bias in eating behavior toward energy-intake exceeding the actual homeostatic demand. Although we cannot infer from our results the etiology of the observed structural differences, our results resemble neural and behavioral differences well known from other forms of addiction, however, with marked differences between women and men. These findings are important for designing gender-appropriate treatments of obesity and possibly its recognition as a form of addiction.

11 November 2005 in Diabetologia
Verified
Journal Article
Open access
PDF file
AHA. Holstein
A. Holstein
MSM. Stumvoll
M. Stumvoll
Metformin is an effective anti-hyperglycaemic and cardioprotective agent, but a long list of contraindications precludes millions of patients with type 2 diabetes from using it. This is largely due to the historical experience of lactic acidosis with phenformin, despite the fact that metformin does not predispose to this when compared with other therapies. Contraindications such as old age, renal impairment and cardiac insufficiency are increasingly disregarded in clinical practice, yet there is no evidence that the incidence of lactic acidosis has changed. Metformin has been shown to improve metabolic control without causing lactic acidosis in elderly patients with multiple comorbidities, including explicit contraindications, and its use in patients with type 2 diabetes over the age of 70 with mild renal impairment did not produce a clinically relevant increase in plasma lactate. There is no correlation between levels of metformin and lactate in patients with lactic acidosis, and its prognosis is mainly related to the causal hypoxic underlying disease and comorbidities. These findings raise doubts about the pathogenetic significance of metformin in lactic acidosis. We propose that advanced age per se, mild renal impairment and compensated heart failure can no longer be upheld as contraindications for metformin. A clear re-definition of contraindications to metformin will enable more physicians to prescribe within guidelines.